Happy Friday. Here's what matters right now. BlackRock's Bitcoin ETF just posted its biggest inflow day in a month, pulling in $269 million. Bitcoin briefly hit $73,000 after a cooler-than-expected core CPI print, but couldn't hold the breakout. Meanwhile, the U.S.-China tariff war hit a new peak — China slapped 125% tariffs on American goods starting tomorrow. And in a quiet but fascinating corner of Bitcoin development, researchers unveiled ways to make Bitcoin quantum-resistant without changing the protocol. Let's get into it.
Let's start with AI in healthcare, because this week brought a cluster of announcements that together paint a pretty clear picture of where drug discovery is heading.
First up, Ataraxis AI launched a product called Ataraxis Breast NEO. It's an AI test that predicts whether a breast cancer patient will respond to neoadjuvant therapy — that's treatment given before surgery to shrink tumors. What's notable is how little tissue it needs. A single core needle biopsy slide at diagnosis, and the model estimates treatment response across major breast cancer subtypes, including HER2-positive and triple-negative. The model was trained on multimodal data from over 1,000 patients and validated in more than 1,500 across multiple studies. It joins two existing Ataraxis tests for recurrence risk and chemotherapy benefit, giving clinicians an end-to-end AI-powered platform from the first biopsy through adjuvant therapy.
Then there's Imagene AI, which announced a collaboration with Daiichi Sankyo to advance biomarker discovery in oncology. This one is particularly interesting because of the data scale involved. Imagene's platform analyzes whole-slide pathology images alongside molecular profiles and clinical outcomes, and it draws on a data lake of over 3.5 million tissue samples. The collaboration focuses on antibody-drug conjugate programs, using AI to move from biomarker hypotheses to robust patient stratification.
And on the small-molecule side, Variational AI released Enki 4, the fourth generation of its drug discovery platform. The key number: target coverage jumped 28%, from 592 to 760 drug targets. That's across GPCRs, kinases, ion channels, proteases, and more. The platform now supports degraders, PROTACs, molecular glues, and novel ADC payloads. The pitch is that Enki can generate novel, potent, synthesizable lead-like molecules pre-trained on the expanded target set, potentially skipping the traditional hit-identification and hit-to-lead stages entirely.
Now, a broader piece on Phys.org this week offered a useful reality check. AI is scanning petabytes of data and speeding up testing, but it can also produce false signals if the data or models mislead. The promise is large but not guaranteed. Results are probabilistic and need continuous validation with experimental data. That's the right framing. These aren't magic boxes. But the direction is unmistakable — AI is compressing timelines in drug development, and the companies building the best multimodal data pipelines are going to have a serious edge.
Alright, let's talk institutional money flowing back into Bitcoin.
Thursday was a strong day for U.S. spot Bitcoin ETFs. Total net inflows across the 12 listed funds came in at $358 million, snapping a two-day streak of outflows. And the headline act was BlackRock's iShares Bitcoin Trust, IBIT, which pulled in $269.3 million — its best single-day performance since early March.
But it wasn't just BlackRock. Fidelity's Wise Origin Bitcoin Fund added $53.3 million. Morgan Stanley's newly launched Bitcoin Trust, MSBT, attracted $14.9 million on just its second day of trading. Bitwise brought in $11.7 million, ARK 21Shares added $4.8 million, and Franklin Templeton and VanEck each contributed around $2 million. That's broad-based demand, not one fund carrying the load.
A few things stand out. Year-to-date, IBIT alone has attracted roughly $1.5 billion in net inflows, even as Bitcoin's price pulled back from its 2026 highs. BlackRock executives say their IBIT investors are predominantly long-term holders, not momentum traders flipping in and out. That's a meaningful signal about the quality of this capital.
Morgan Stanley is worth watching here too. Their digital assets chief, Amy Oldenburg, called MSBT the firm's best-performing ETF launch to date. And they're not stopping — the bank has indicated plans for more crypto ETF products, including staked Ether and Solana ETFs.
Zooming out, U.S. spot Bitcoin ETFs closed 2025 with about $56.59 billion in cumulative net inflows. After Thursday, the running total sits around $56.51 billion — just $80 million short of where things stood at the start of the year. So despite a significant drawdown in Bitcoin's price, almost none of that institutional capital actually left.
That's the story. The price can wobble, geopolitics can flare up, but the structural bid from institutions through regulated ETF products appears durable. Whether that translates into a sustained breakout above $73,000 is another question, but the plumbing for the next leg up is being laid right now.
Now for something genuinely interesting on the Bitcoin development side. Two separate efforts emerged this week to make Bitcoin quantum-resistant, and neither requires a protocol upgrade.
The bigger splash came from a StarkWare researcher who introduced something called Quantum Safe Bitcoin, or QSB. Here's the idea: instead of relying on traditional elliptic-curve signatures, which a sufficiently powerful quantum computer could break using Shor's algorithm, QSB uses a hash-to-signature puzzle. To spend Bitcoin, you brute-force a hash input that produces an output resembling a valid ECDSA signature. That brute-forcing has no known quantum shortcut, giving you roughly 118 bits of pre-image resistance based on about 70.4 trillion attempts.
The clever part is that this works within Bitcoin's existing scripting framework. No soft fork. No miner signaling. No consensus change. It's an emergency fallback you could use today.
The catch? Cost. The FX Leaders report puts it at $75 to $150 per transaction in GPU compute. CoinDesk's reporting cites around $200. Either way, it's wildly impractical for everyday payments. But for safeguarding large holdings against a future quantum threat? That's a different calculus entirely. If you've got 100 Bitcoin sitting in a wallet and quantum computers start looking real, paying $150 to move those funds to safety is nothing.
There are limitations. QSB doesn't protect coins already locked in old P2PK addresses where public keys are already exposed. And it doesn't cover Lightning Network channels.
Separately, Lightning Labs CTO Olaoluwa Osuntokun unveiled a working prototype of a quantum-resistant wallet rescue tool. This one provides an escape hatch for users to prove they created a wallet with its secret seed — without revealing the seed — in case a future quantum defense upgrade disables current signature paths like Taproot. Think of it as insurance against the worst-case scenario where Bitcoin does a hard pivot to quantum resistance and millions of wallets suddenly can't sign transactions.
Both of these sit alongside the longer-term BIP-360 proposal, which was merged in February and would eventually add post-quantum signatures to Bitcoin through a proper soft fork.
The community remains divided on urgency. Some think quantum threats are decades away. Others point to Google's March 2026 paper and say the timeline is compressing faster than expected. Either way, having working fallbacks before you need them is exactly how Bitcoin should be thinking about this.
Finally, the macro backdrop. It's messy, and Bitcoin is navigating it with surprising composure.
Let's start with inflation. March CPI came in with a split personality. Headline inflation soared to 3.3%, the largest jump since 2021, driven overwhelmingly by energy costs tied to the Iran conflict — gas prices saw their biggest spike in 60 years. But core CPI, stripping out food and energy, rose just 0.2% month-over-month, below the 0.3% forecast. That softer core reading is what markets latched onto. Bitcoin briefly hit $73,000 on the print.
But it didn't hold. Bitcoin has now failed to break above $73,000 for the third time since the ceasefire, and Glassnode's on-chain analysis from this week noted the recent bounce from $67,000 to $72,000 still fits the fingerprint of a bear market rebound. The key level to watch is $75,000. Analysts say that needs to break convincingly before anyone should call this a genuine bullish phase.
On the institutional positioning side, there's a telling signal. Institutions are buying $80,000 call options on Bitcoin, but they're simultaneously loading up on downside protection. It's a bet-but-hedge posture — conviction without full commitment.
Meanwhile, the U.S.-China trade war escalated sharply. China announced 125% tariffs on American goods effective April 12, matching what it called a ceiling in response to U.S. duties that reached as high as 145%. Beijing went beyond tariffs too, adding 12 U.S. companies to its export control list and placing 6 on its Unreliable Entity List. The People's Bank of China let the yuan weaken to support exporters.
Here's the interesting thing for Bitcoin. GDP growth was revised down to just 0.5% in Q4 2025, a dramatic slowdown from 4.4% the prior quarter. The economy is close to stalling, but inflation is still too hot for an easy Fed rescue. That's the worst possible setup for traditional monetary policy and arguably the best possible argument for an apolitical, fixed-supply asset.
Bitcoin mining economics tell a similar story. Fees are near zero, the cost to mine is approaching $80,000, and difficulty is projected to drop about 5% on April 18. The network is running on the subsidy, not demand. That's not a crisis — it's a compression that historically precedes the next expansion.
On the regulatory front, the CLARITY Act is getting an unprecedented push from the White House, with Treasury and the SEC coordinating pressure on the Senate to pass it before the 2026 midterms. Coinbase CEO Brian Armstrong publicly backed Treasury Secretary Bessent's push, a notable reversal from his stance 3 months ago when he said Coinbase couldn't support the bill as written. Something shifted. And Japan approved a bill classifying crypto as financial instruments, with insider-trading bans and disclosure requirements that signal the regulatory mainstreaming of this asset class globally.
Here's the thought to sit with heading into the weekend. Bitcoin has working quantum fallbacks before it actually needs them, $358 million in fresh institutional capital flowing through ETFs in a single day, and a macro environment that's slowly but relentlessly making the case for a non-sovereign store of value. The price hasn't caught up to the fundamentals yet. Whether it does depends on $75,000. Watch that level. Have a good weekend.